Liraglutide Improve Cognitive Function in Patients With Type 2 Diabetes Mellitus

NCT05360147 · Completed

Last updated 2026-05-28

This clinical trial tested whether the medication liraglutide could improve thinking and memory in adults with type 2 diabetes over a 12-week period.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, single-blind treatment study

Participants 30 people

Who can join Ages 18–65 · all sexes

Timeline Started 2021-01 · est. completion 2021-05

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT05360147 ↗

Description as written by the study sponsor.

Patients with diabetes are susceptible to dementia, but regular therapy fails to reduce the risk of dementia. In previous observational study, the investigators found that liraglutide can improve cognitive function in patients with T2DM through a metabolism-independent pathway. Here the investigators aim to further verify such effects through a randomized, controlled study.

Treatments tested

Liraglutide Drug

Liraglutide is a glucagon-like peptide type 1 (GLP-1) analogue. We had fond its cognitive improvement effects in an observational study. In order to confirm the effects, the investigators conduct a randomized, controlled study.
Oral antidiabetic drugs: Metformin, Sulfonylureas (2nd generation), Thiazolidinediones, α-Glucosidase inhibitors, and Glinides Drug

oral antidiabetic drugs (OADs) or insulin, except for glucagon-like peptide type 1 (GLP-1) analogues

Main thing measured	Changes in cognitive function from baseline to 12 weeks
Sponsor	Third Military Medical University
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05360147 ↗